Literature DB >> 20329045

Biopharmaceutical properties of solid dosage forms.

R A Chapman.   

Abstract

Year:  1967        PMID: 20329045      PMCID: PMC1923340     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  10 in total

Review 1.  TABLET DISINTEGRATION AND PHYSIOLOGICAL AVAILABILITY OF DRUGS.

Authors:  A B MORRISON; J A CAMPBELL
Journal:  J Pharm Sci       Date:  1965-01       Impact factor: 3.534

2.  Oral prolonged-action medication.

Authors:  J A CAMPBELL; A B MORRISON
Journal:  JAMA       Date:  1962-07-14       Impact factor: 56.272

3.  Criteria for oral sustained release medication with particular reference to amphetamine.

Authors:  J A CAMPBELL; E NELSON; D G CHAPMAN
Journal:  Can Med Assoc J       Date:  1959-07-01       Impact factor: 8.262

4.  The relation between in vitro disintegration time of sugar-coated tablets and physiological availability of riboflavin.

Authors:  D G CHAPMAN; R CRISAFIO; J A CAMPBELL
Journal:  J Am Pharm Assoc Am Pharm Assoc       Date:  1954-05

5.  Biopharmaceutical properties of solid dosage forms.

Authors:  M Pernarowski
Journal:  Can Med Assoc J       Date:  1967-07-22       Impact factor: 8.262

6.  Biopharmaceutical properties of solid dosage forms.

Authors:  J Hendry
Journal:  Can Med Assoc J       Date:  1967-07-22       Impact factor: 8.262

7.  Implications of enzyme induction in drug toxicity studies.

Authors:  R M Welch; Y E Harrison; J J Burns
Journal:  Toxicol Appl Pharmacol       Date:  1967-03       Impact factor: 4.219

8.  The biopharmaceutical properties of solid dosage forms. I. An evaluation of 23 brands of phenylbutazone tablets.

Authors:  R O Searl; M Pernarowski
Journal:  Can Med Assoc J       Date:  1967-06-10       Impact factor: 8.262

9.  The physiological disposition of phenylbutazone (butazolidin) in man and a method for its estimation in biological material.

Authors:  J J BURNS; R K ROSE; T CHENKIN; A GOLDMAN; A SCHULERT; B B BRODIE
Journal:  J Pharmacol Exp Ther       Date:  1953-11       Impact factor: 4.030

10.  Benefits and toxicity of phenylbutazone (butazolidin) in rheumatoid arthritis.

Authors:  C A L STEPHENS; E E YEOMAN; W P HOLBROOK; D F HILL; W L GOODIN
Journal:  J Am Med Assoc       Date:  1952-11-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.